285 related articles for article (PubMed ID: 25886818)
21. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
Zhang Y; Kolesar JM
Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
[TBL] [Abstract][Full Text] [Related]
22. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag.
Erickson-Miller CL; Kirchner J; Aivado M; May R; Payne P; Chadderton A
Leuk Res; 2010 Sep; 34(9):1224-31. PubMed ID: 20202683
[TBL] [Abstract][Full Text] [Related]
23. Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation.
Tanaka T; Inamoto Y; Yamashita T; Fuji S; Okinaka K; Kurosawa S; Kim SW; Tanosaki R; Fukuda T
Biol Blood Marrow Transplant; 2016 May; 22(5):919-24. PubMed ID: 26785333
[TBL] [Abstract][Full Text] [Related]
24. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH;
N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027
[TBL] [Abstract][Full Text] [Related]
25. Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
Pathak S; Roth M; Verma A; Steidl U
Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1667-75. PubMed ID: 24215532
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
Modi Y; Shaaban H; Gauchan D; Maroules M
J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
[TBL] [Abstract][Full Text] [Related]
27. A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag.
Suzuki N; Hiraga J; Hariyama Y; Takagi Y; Ohashi H; Kishigami Y; Oguchi H; Kagami Y
Int J Hematol; 2018 Jul; 108(1):109-111. PubMed ID: 29188582
[TBL] [Abstract][Full Text] [Related]
28. Eltrombopag: a novel oral thrombopoietin receptor agonist.
Corman SL; Mohammad RA
Ann Pharmacother; 2010 Jun; 44(6):1072-9. PubMed ID: 20460556
[TBL] [Abstract][Full Text] [Related]
29. Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.
Erickson-Miller CL; Pillarisetti K; Kirchner J; Figueroa DJ; Ottesen L; Martin AM; Liu Y; Kamel YM; Messam C
BMC Cancer; 2012 Sep; 12():405. PubMed ID: 22967017
[TBL] [Abstract][Full Text] [Related]
30. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.
Kao YR; Chen J; Narayanagari SR; Todorova TI; Aivalioti MM; Ferreira M; Ramos PM; Pallaud C; Mantzaris I; Shastri A; Bussel JB; Verma A; Steidl U; Will B
Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209246
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias.
Wesson W; Ahmed N; Rashid A; Tabak C; Logan E; Marchena-Burgos J; Nelson M; Davis JA; McGann M; Shune L; Hoffmann M; Abdallah AO; Hashmi H
Eur J Haematol; 2024 Apr; 112(4):538-546. PubMed ID: 38044594
[TBL] [Abstract][Full Text] [Related]
32. Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists.
Kazemi T; Martin S; Worswick S
Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617608
[TBL] [Abstract][Full Text] [Related]
33. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
34. Protein and Small-Molecule Leucopoiesis and Thrombopoiesis Stimulators.
Farsa O; Zubáč P
Mini Rev Med Chem; 2021; 21(13):1638-1645. PubMed ID: 33390132
[TBL] [Abstract][Full Text] [Related]
35. Identification of anti-thrombopoietin receptor antibody in prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation treated successfully with eltrombopag.
Fujimi A; Kamihara Y; Hashimoto A; Kanisawa Y; Nakajima C; Hayasaka N; Yamada S; Okuda T; Minami S; Ono K; Iyama S; Kato J
Int J Hematol; 2015 Oct; 102(4):471-6. PubMed ID: 25964100
[TBL] [Abstract][Full Text] [Related]
36. Eltrombopag for the treatment of immune thrombocytopenia.
Cheng G
Expert Rev Hematol; 2011 Jun; 4(3):261-9. PubMed ID: 21671710
[TBL] [Abstract][Full Text] [Related]
37. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
Hayes S; Mudd PN; Ouellet D; Johnson BM; Williams D; Gibiansky E
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1507-20. PubMed ID: 23564375
[TBL] [Abstract][Full Text] [Related]
38.
D'Alò F; Zangrilli I; Cupelli E; Fianchi L; Criscuolo M; Falconi G; Fabiani E; Pagano L; Hohaus S; De Stefano V
Platelets; 2021 Apr; 32(3):378-382. PubMed ID: 32268817
[TBL] [Abstract][Full Text] [Related]
39. A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists.
Xie CY; Xu YP; Zhao HB; Lou LG
Exp Hematol; 2012 May; 40(5):386-92. PubMed ID: 22269115
[TBL] [Abstract][Full Text] [Related]
40. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
Imbach P; Crowther M
N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
